<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02298010</url>
  </required_header>
  <id_info>
    <org_study_id>ML29471</org_study_id>
    <nct_id>NCT02298010</nct_id>
  </id_info>
  <brief_title>Lymph Node Metastasis in Extended Lymphadenectomy for Gastric Cancer From a CLASSIC Trial</brief_title>
  <official_title>Pattern and Clinical Implication of Lymph Node Metastasis From Gastric Cancer Which Was Resected by Radical Surgery With Extended Lymphadenectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Saint Vincent's Hospital, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gachon University Gil Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyungpook National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Keimyung University Dongsan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kosin University Gospel Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul Veterans Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Soonchunhyang University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ajou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yeungnam University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea Cancer Center Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ewha Womans University Mokdong Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pattern of lymph node metastasis of the gastric cancer to each geographic lymph nose&#xD;
      stations and the relation between each metastasis and survival are to be analyzed by&#xD;
      retrospective review of medical records of who enrolled in the CLASSIC trial (NCT00411229)&#xD;
      which have compared adjuvant chemotherapy and no adjuvant therapy after radical gastrectomy&#xD;
      with extended lymphadenectomy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Topographic pattern of metastasis to regional lymph node stations</measure>
    <time_frame>at the time of surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival according to the metastatic lymph node station</measure>
    <time_frame>3 and 5years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival according to lymph node ratio</measure>
    <time_frame>3 and 5years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recurrence pattern</measure>
    <time_frame>3 and 5years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">899</enrollment>
  <condition>Stomach Neoplasms</condition>
  <condition>Cancer of Lymph Node</condition>
  <arm_group>
    <arm_group_label>Adjuvant chemotherapy group</arm_group_label>
    <description>Research subjects who were enrolled in CLASSIC trial and underwent adjuvant chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Only surgery group</arm_group_label>
    <description>Research subjects who were enrolled in CLASSIC trial and did not undergo adjuvant chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine, oxaliplatin</intervention_name>
    <arm_group_label>Adjuvant chemotherapy group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Study subjects who were enrolled in CLASSIC trial (NCT00411229) and whose medical records&#xD;
        about the extent of the lymph node dissection and pathologic report are available.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Criteria of previous CLASSIC trial:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        To be eligible for inclusion, each patient must fulfill each of the following criteria:&#xD;
&#xD;
          -  Ambulatory males or females, aged ≥18 years.&#xD;
&#xD;
          -  Karnofsky performance status of ≥70 %.&#xD;
&#xD;
          -  Histologically confirmed gastric adenocarcinoma, staged pathologically, AJCC/UICC&#xD;
             stage II (T2N1, T1N2, T3N0), IIIa (T3N1, T2N2, T4N0), and IIIb (T3N2). At least 15&#xD;
             examined lymph nodes are required to ensure the adequate TNM classification)&#xD;
&#xD;
          -  Patients who underwent curative D2 lymphadenectomy resection for gastric cancer with&#xD;
             no macroscopic or microscopic evidence for remaining tumor, who can be randomized to&#xD;
             either study arm within 6 weeks after surgery.&#xD;
&#xD;
          -  Give written informed consent prior to study specific screening procedures, with the&#xD;
             understanding that the patient has the right to withdraw from the study at any time,&#xD;
             without prejudice.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients who fulfill any of the following criteria will be excluded:&#xD;
&#xD;
          -  Serious concomitant medical illnesses that would limit life expectancy to &lt; 5 years.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Women of childbearing potential with either a positive or no pregnancy test at&#xD;
             baseline. Postmenopausal women must have been amenorrheic for at least 12 months to be&#xD;
             considered of non-child bearing potential.&#xD;
&#xD;
          -  Sexually active males and females (of childbearing potential) unwilling to practice&#xD;
             contraception during the study.&#xD;
&#xD;
          -  Any evidence of metastatic disease (including presence of tumor cells in the ascites).&#xD;
&#xD;
          -  Previous cytotoxic chemotherapy, radiotherapy or immunotherapy except corticosteroids,&#xD;
             for the currently treated gastric cancer.&#xD;
&#xD;
          -  History of another malignancy within the last five years except cured basal cell&#xD;
             carcinoma of skin and cured carcinoma in-situ of uterine cervix.&#xD;
&#xD;
          -  History of uncontrolled seizures, central nervous system disorders or psychiatric&#xD;
             disability judged by the Investigator to be clinically significant precluding informed&#xD;
             consent or interfering with compliance for oral drug intake.&#xD;
&#xD;
          -  Clinically significant (i.e. active) cardiac disease e.g. symptomatic coronary artery&#xD;
             disease, New York Heart Association (NYHA) grade II or greater congestive heart&#xD;
             failure or serious cardiac arrhythmia requiring medication or myocardial infarction&#xD;
             within the last 12 months.&#xD;
&#xD;
          -  Lack of physical integrity of the upper gastrointestinal tract or those who have&#xD;
             malabsorption syndrome likely to influence absorption of capecitabine, or inability to&#xD;
             take oral medication.&#xD;
&#xD;
          -  Known peripheral neuropathy ≥ CTCAEv3 grade 1. Absence of deep tendon reflexes (DTRs)&#xD;
             as the sole neurologic abnormality does not render the patient ineligible.&#xD;
&#xD;
          -  Organ allografts requiring immunosuppressive therapy.&#xD;
&#xD;
          -  Serious uncontrolled intercurrent infections or other serious uncontrolled concomitant&#xD;
             disease.-&#xD;
&#xD;
          -  Moderate or severe renal impairment [creatinine clearance equal to or below 50 ml/min&#xD;
             (calculated according to Cockroft and Gault)], or serum creatinine &gt; 1.5 x upper limit&#xD;
             of normal (ULN).&#xD;
&#xD;
          -  Any of the following laboratory values:&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &lt; 1.5 x 10^9/L&#xD;
&#xD;
          -  Platelet count &lt; 100 x 10^9/L&#xD;
&#xD;
          -  Total bilirubin &gt; 1.5 x ULN&#xD;
&#xD;
          -  ALAT, ASAT &gt; 2.5 x ULN&#xD;
&#xD;
          -  Alkaline phosphatase &gt; 2.5 x ULN.&#xD;
&#xD;
          -  Prior unanticipated severe reaction to fluoropyrimidine therapy (with or without&#xD;
             documented DPD deficiency) or patients with Kknown dihydropyrimidine dehydrogenase&#xD;
             (DPD) deficiency.&#xD;
&#xD;
          -  Hypersensitivity to platinum compounds or any of the components of the study&#xD;
             medications.&#xD;
&#xD;
          -  Received any investigational drug or agent/procedure, i.e. participation in another&#xD;
             trial, within 4 weeks before randomization.&#xD;
&#xD;
          -  Blood transfusions or growth factors to aid hematologic recovery within 2 weeks prior&#xD;
             to study treatment start.&#xD;
&#xD;
          -  Requirement for concurrent use of the antiviral agent sorivudine (antiviral) or&#xD;
             chemically related analogues, such as brivudine.&#xD;
&#xD;
          -  Unwilling or unable to comply with the protocol for the duration of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>November 19, 2014</study_first_submitted>
  <study_first_submitted_qc>November 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2014</study_first_posted>
  <last_update_submitted>May 12, 2019</last_update_submitted>
  <last_update_submitted_qc>May 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Lymphatic Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

